UBS Put 25.5 FRE 20.12.2024/ DE000UL9HJ03 /
15.11.2024 17:40:50 | Изменение-0.002 | Бид- | Предложение- | Базовый актив | Цена исполнения | Дата истечения | Тип опциона |
---|---|---|---|---|---|---|---|
0.140EUR | -1.41% | - Величина цены спроса: - |
- Величина цены предложения: - |
FRESENIUS SE+CO.KGAA... | 25.50 - | 20.12.2024 | Put |
GlobeNewswire
23.04
Transferring Biomedical Research to Patients Faster: ForTra gGmbH Announces Positive Funding Track R...
GlobeNewswire
23.02
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatm...
GlobeNewswire
04.09.2023
CIO Leadership: Generative AI and Visionary Leadership in the Enterprise Will Power the Discussion a...
GlobeNewswire
31.08.2023
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
GlobeNewswire
24.08.2023
CIO Leadership: The Steps Needed to Build a High-Performance Culture Will Power the Discussion at th...
GlobeNewswire
25.02.2022
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodia...
GlobeNewswire
05.01.2022
Oculis appoints Mr. Webb Ding as Global Chief Operating Officer and General Manager (China)
GlobeNewswire
31.12.2021
CIO Leadership: HMG Strategy, the World’s #1 Executive Leadership Network, Looks Ahead to its 15th Y...
GlobeNewswire
09.12.2021
Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surge...
GlobeNewswire
22.11.2021
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology
GlobeNewswire
22.11.2021
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology
- Первая страница
- Назад
- 1
- 2
- 3
- 4
- Следующий
- Последняя страница